DUBLIN, April 23, 2020 /PRNewswire/ -- The "Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Stem cell therapies are viable alternatives to conventional treatments with substantial therapeutic potential; market opportunities are huge, as multiple product candidates are expected to be approved over the coming decade.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for stem cell therapies over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved stem cell therapies.

The report also features the likely distribution of the current and forecasted opportunity within stem cell therapies market across:

According to the WHO, in 2020, nearly 75% of fatalities that are estimated to be reported across the globe, are likely to be caused due to diseases, such as chronic stroke disease, diabetes, cancer, heart disease, and certain mental health conditions. In addition, as per a report published by the Center for Managing Chronic Disease, University of Michigan, more than 50% of the global population was estimated to be living with some form of chronic illness.

The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options. Despite advances in healthcare, there is an evident lack of permanent treatment solutions for many aforementioned diseases. Majority of the currently available treatment options focus on palliative care and are incapable of addressing the root cause of disease, therefore, are unable to improve quality of life of patients.

Since the first bone marrow transplant in 1950s, these regenerative cellular therapies have garnered significant attention within the biopharmaceutical industry. Over the years, advances in the field of cell biology and regenerative medicine have led to the development of a number of stem cell therapies, which are believed to possess the potential to address several unmet needs related to the treatment of a wide range of disease conditions. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms.

In fact, such interventions have also been shown to enable cell regeneration, restoring normal functioning capabilities in affected organs. Till date, nearly 25 stem cell-based therapies have been approved; popular examples include EYE-01M (2019), Alofisel (2018), MACI (2016), Stempeucel (2016) and Strimvelis (2016). Further, several such therapies are presently being evaluated across 540 active clinical trials worldwide. This emerging field of research has received significant capital investments from several big pharma companies and venture capital funds / investors.

Despite the associated optimism, the growth of this market is stunted by a number of development and manufacturing related challenges, primarily revolving around the limited availability of the required expertise and infrastructure to produce such products. However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term.

In addition to other elements, the study includes:

To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

Key Topics Covered

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION 3.1. Chapter Overview3.2. Overview of Stem Cell Therapies3.3. Regulatory Guidelines for Stem Cell Therapies3.4. Prevalent Trends Related to Stem Cell Therapies3.5. Growth Drivers and Roadblocks

4. MARKET LANDSCAPE4.1. Chapter Overview4.2. Stem Cell Therapies: Marketed and Development Pipeline4.3. Stem Cell Therapies: Additional Information4.4. Stem Cell Therapies: List of Technology Platforms4.5. Stem Cell Therapies: List of Therapy Developers4.6. Heptagon Representation: Analysis by Phase of Development and Key Therapeutic Area4.7. Grid Representation: Analysis by Phase of Development, Source of Stem Cell and Therapeutic Area4.8. Tree Map Representation: Analysis by Therapeutic Area and Size of the Company4.9. World Map Representation: Analysis of Regional Activity

5. COMPANY PROFILES5.1. Chapter Overview5.2. Anterogen5.2.1. Company Overview5.2.2. Product Portfolio: Clinical-Stage Stem Cell Therapies5.2.3. Recent Developments and Future Outlook5.3. Athersys5.4. CHA Biotech5.5. Cytopeutics5.6. Hope Biosciences5.7. Mesoblast5.8. Pluristem Therapeutics5.9. Takeda Pharmaceutical5.10. TICEBA

6. KEY THERAPEUTIC AREAS6.1. Chapter Overview6.2. Autoimmune / Inflammatory Disorders6.3. Cardiovascular Disorders6.4. Dermatological Disorders6.5. Metabolic Disorders6.6. Oncological Disorders6.7. Neurological Disorders

7. ANSOFF MATRIX EVALUATION7.1. Chapter Overview7.2. Established Therapeutic Areas in Established Regions7.2.1. Competition7.2.2. Growth Opportunities7.3. Established Therapeutic Areas in Emerging Regions7.4. Emerging Therapeutic Areas in Established Regions7.5. Emerging Therapeutic Areas in Emerging Regions

8. ACADEMIC GRANTS ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Stem Cell Therapies: Analysis of Grants Awarded by the National Institutes of Health (NIH)8.4. Grant Attractiveness Analysis

9. CLINICAL TRIAL ANALYSIS9.1. Chapter Overview9.2. Scope and Methodology9.3. Stem Cell Therapies: Clinical Trial Analysis

10. STEM CELL MANUFACTURING MARKET LANDSCAPE AND KPIs FOR EVALUATING CONTRACT SERVICES PARTNERS10.1. Chapter Overview10.2. Stem Cell Therapy Manufacturing10.3. Stem Cell Therapy Manufacturing: KPI Analysis10.4. Concluding Remarks

11. STEM CELL THERAPY DEVELOPERS AND CMOs: OPPORTUNITY ASSESSMENT11.1. Chapter Overview11.2. Therapy Developers and CMOs in North America11.3. Therapy Developers and CMOs in Europe11.4. Therapy Developers and CMOs in Asia-Pacific and Rest of the World11.5. Concluding Remarks

12. KEY COMMERCIALIZATION STRATEGIES12.1. Chapter Overview12.2. Successful Drug Launch Strategy: ROOTS Framework12.3. Successful Drug Launch Strategy: Product Differentiation12.4. Commonly Adopted Commercialization Strategies based on Stage of Product Development12.5. Key Approved Stem Cell Therapies: Profiles12.5.1. CARTISTEM12.5.2. HiQCell12.5.3. Prochymal12.5.4. Strimvelis12.6. Key Commercialization Strategies Adopted by Stem Cell Therapy Developers12.6.1. Strategies Adopted before Therapy Approval12.6.2. Strategies Adopted Post Therapy Approval12.7. Opportunities and Challenges with Unapproved Therapies12.8. Concluding Remarks

13. MARKET FORECAST13.1. Chapter Overview13.2. Scope and Limitations13.3. Forecast Methodology and Key Assumptions13.4. Overall Stem Cell Therapies Market, 2020-203013.5. Concluding Remarks

14. CONCLUSION

15. EXECUTIVE INSIGHTS15.1. Chapter Overview15.2. Seraxis15.3. Xcelthera15.4. Kadimastem15.5. Heartseed15.6. University of Rostock15.7. Bio Elpida15.8. Roslin Cell Therapies15.9. University of Minnesota15.10. Waisman Biomanufacturing15.11. YposKesi

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/r95p7c

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See the rest here:
Stem Cells Market Outlook with a Focus on Clinical Therapies 2020-2030: Types of Stem Cells, Route of Administration, Therapeutic Areas, End-users,...